hrp0098fc13.4 | Pituitary, Neuroendocrinology and Puberty 2 | ESPE2024

Relationship between the timing of the physical changes of puberty and total pubertal growth in healthy adolescents: new insights which can provide helpful clinical guidance

Yan Georgina , Holmgren Anton , Albertsson-Wikland Kerstin , Butler Gary

Introduction: In healthy adolescents, there is significant inter-individual variation in the timing of peak height velocity (PHV) and the total growth achieved during puberty. The relationship between physical changes of puberty and pubertal growth has been studied previously, but further detail is needed for use in clinical practice, especially where there are worries that early or late pubertal onset will curtail the magnitude of the pubertal growth spurt. O...

hrp0098fc1.5 | Diabetes and Insulin | ESPE2024

The Side-Effects of Lanreotide in Children with Congenital Hyperinsulinism (CHI): A Decade-long Exploration

Malhotra Neha , Yan Georgina , Morgan Kate , Gilbert Clare , Doodson Louise , Gan Chin , Dastamani Antonia

Background: Lanreotide, a prolonged-release somatostatin analogue, has been utilized off-label for nearly a decade to treat cases of congenital hyperinsulinism (CHI) that do not respond to diazoxide. Acute side-effects of Lanreotide include diarrhoea and topical allergic reactions. Long-term effects include hepatitis, gallstones, growth suppression, hypothyroidism and gastrointestinal dysmotility. However, limited number of case series have documented the long...